Network Version
Paricalcitol Data Sheet
| Product Name: | Paricalcitol |
 |
|---|---|---|
| CAS No.: | 131918-61-1 | |
| Cat. No.: | HY-50919 | |
| MWt: | 416.64 | |
| Formula: | C27H44O3 | |
| Purity : | >98% | |
| Solubility: | DMSO : 100 mg/mL (240.02 mM; Need ultrasonic); Ethanol : 12.5 mg/mL (30.00 mM; Need ultrasonic) | |
| Mechanisms: | Target: Cancer Metabolic Disease | |
| Biological Activity: | ||
| Paricalcitol, a vitamin D analogue, is a vitamin D receptor agonist, used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure. In Vitro: Paricalcitol (3×10-8 M; HP + PC) produces a significant reduction in calcification relative to the observed in cells in HP medium. Paricalcitol causes a reduction in the levels of nuclear β-catenin to a level similar to that observed in control cells[1]. In Vivo: Paricalcitol (300 ng/kg/day) significantly decreases Tau, and prevents LV dysfunction in mice. Paricalcitol reduces mRNA expression of ANP, fibronectin and collagen III in the TAC-pari mice[2]. | ||
1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com